It can be shown that treatment bringing back independence is less costly than the nursing homes and medical staff.

$AVXL This may show why Anavex is definitely on the right path by using patients personal genetics to determine dosage.

Pill = best possible treatment course.

Many claim him to be selfish and unconcerned with others, I see a different Missling, with humility and a deep concern for patients who are suffering.

Half the patients improved over baseline over 1 year.

Blarcamesine’s Phase III clinical trials show similar levels of significant improvement in communication and interaction, as patients had statistically significant improvement in the RSBQ primary endpoint of 72.2% compared to 38.5% on placebo. .

And better still for just those 85% carrying the normal SigmaR1 gene as well as for APOE2 and 3 patients.

new clinical trial results show great promise for treating early Alzheimer’s, giving renewed hope for effective treatments.

Anavex has over 760 patients that have taken it without any significant issues. .

“We believe the use of BX1000, combined with our reversal agent, BX3000, could make for precise control of timing under neuromuscular paralysis for surgical patients, which could result in time and cost savings for patients and hospitals alike.

This could be significantly impactful for patients, surgeons, and anesthesiologists by enhancing safety, and possibly saving time and reducing costs related to delayed recovery from neuromuscular paralysis following surgical procedures.”

It's a miracle drug for patients that suffer with cronic osteoarthritis.

It is a game changer for heart patients and is being rapidly adopted by hospitals and doctors.

$SLRX 'We believe this interim data is an encouraging development for these patients in need of new treatment options and we are looking forward to an additional data update next month.”

$SLRX “These initial data explain why we believe SP-3164 is so exciting, with the potential to make a positive difference in the treatment of hematologic cancers.